BUZZ - Bristol-Myers Squibb raises full-year revenue guidance and beats expectations in the third quarter, sending its stock price higher

October 29 - ** Bristol Myers Squibb (BMY.N) shares rose 2.2% pre-market to $61.94

** The pharmaceutical giant raised its annual revenue forecast (link) from a previous estimate of $49 billion–$50 billion to $49.75 billion–$50.25 billion

** According to data compiled by London Stock Exchange Group (LSEG), the company reported third-quarter adjusted earnings per share of $1.35, higher than the analyst consensus estimate of $1.14

** BMY's third-quarter revenue was $13.1 billion, exceeding the market expectation of $12.75 billion

** The company now expects its 2026 adjusted earnings per share to be $6.35–$6.55, down from its previous forecast of $6.75–$7.00

** As of the close of the previous trading day, BMY shares had risen 12.3% year-to-date

(To assist non-English speakers, Reuters has automatically translated this report into several other languages. Because automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translated text and provides it only for readers’ convenience. Reuters accepts no responsibility for any damage or loss arising from the use of automated translation.)